{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T14:17:42Z","timestamp":1784557062229,"version":"3.55.0"},"reference-count":38,"publisher":"Bioscientifica","issue":"4","license":[{"start":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:00:00Z","timestamp":1721779200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["etj.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,7,24]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Patients with non-medullary thyroid carcinoma (NMTC) that are refractory to radioactive iodine (RAI) have a poor prognosis. Strategies for restoring the ability to take up iodine, so-called redifferentiation, are promising but not suitable for all patients. Preclinical studies, in human cell lines just as in a murine model, have shown that the cardiac glycoside digoxin restored RAI uptake. This prospective single-center open-label study aimed to investigate whether treatment with digoxin could reinduce clinically relevant RAI uptake in patients with metastasized RAI-refractory NMTC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Eight patients with metastasized RAI-refractory NMTC were included between November 2022 and June 2023. Before treatment, a baseline [\n                      <jats:sup>123<\/jats:sup>\n                      I]NaI scintigraphy was performed. Thereafter, patients were treated with digoxin for 3 weeks. Starting doses depended on age and weight. For safety reasons, the usual therapeutic range was aimed for. After 1 week, the digoxin plasma concentration was measured, and the digoxin dose was adjusted if necessary. After 3 weeks of digoxin treatment, a second [\n                      <jats:sup>123<\/jats:sup>\n                      I]NaI scintigraphy was performed. RAI uptake was compared between the two scintigraphies.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Seven patients completed the digoxin treatment and were evaluable. None of the seven patients showed clinically relevant RAI uptake after digoxin treatment. No digoxin-related serious adverse events occurred during this trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Contrary to results from preclinical trials, in this trial, 3 weeks of digoxin treatment did not reinduce RAI uptake in patients with NMTC. This highlights essential challenges regarding the approach toward optimization of studies aimed to restore the RAI uptake and its therapeutic efficacy through drug repurposing.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1530\/etj-24-0153","type":"journal-article","created":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T14:13:27Z","timestamp":1721830407000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-16","source":"Crossref","is-referenced-by-count":5,"title":["Digoxin treatment does not reinduce radioiodine uptake in radioiodine refractory non-medullary thyroid carcinoma"],"prefix":"10.1530","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8503-4140","authenticated-orcid":true,"given":"Pepijn","family":"van Houten","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Division of Endocrinology, Radboud University Medical Center, Nijmegen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Nagarajah","sequence":"additional","affiliation":[{"name":"Roentgeninstitut Duesseldorf, Duesseldorf, Germany"},{"name":"Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janneke E W","family":"Walraven","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Jaeger","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Endocrinology, Radboud University Medical Center, Nijmegen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana C H","family":"van Engen-van Grunsven","sequence":"additional","affiliation":[{"name":"Department of Pathology, Radboud University Medical Center, Nijmegen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes W","family":"Smit","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Endocrinology, Radboud University Medical Center, Nijmegen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romana T","family":"Netea-Maier","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Endocrinology, Radboud University Medical Center, Nijmegen, the Netherlands"},{"name":"Research Center for Functional Genomics, Biomedicine and Translational Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","reference":[{"key":"bib1","series-title":"Lancet. Diabetes and Endocrinology","first-page":"264","article-title":"The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020","volume":"10","author":"Pizzato","year":"2022","unstructured":"Pizzato MLi MVignat JLaversanne MSingh DLa Vecchia C & Vaccarella S. The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020. Lancet. Diabetes and Endocrinology202210264\u2013272. (https:\/\/doi.org\/10.1016\/S2213-8587(2200035-3)"},{"key":"bib2","series-title":"Thyroid","first-page":"461","article-title":"Controversies, consensus, and collaboration in the use of 131I therapy in differentiated thyroid cancer: a joint statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European Thyroid Association","volume":"29","author":"Tuttle","year":"2019","unstructured":"Tuttle RMAhuja SAvram AMBernet VJBourguet PDaniels GHDillehay GDraganescu CFlux GF\u00fchrer D, et al. Controversies, consensus, and collaboration in the use of 131I therapy in differentiated thyroid cancer: a joint statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European Thyroid Association. Thyroid201929461\u2013470. (https:\/\/doi.org\/10.1089\/thy.2018.0597)"},{"key":"bib3","series-title":"European Thyroid Journal","first-page":"227","article-title":"2019 European Thyroid association guidelines for the treatment and follow-up of advanced radioiodine-refractory thyroid cancer","volume":"8","author":"Fugazzola","year":"2019","unstructured":"Fugazzola LElisei RFuhrer DJarzab BLeboulleux SNewbold K & Smit J. 2019 European Thyroid association guidelines for the treatment and follow-up of advanced radioiodine-refractory thyroid cancer. European Thyroid Journal20198227\u2013245. (https:\/\/doi.org\/10.1159\/000502229)"},{"key":"bib4","series-title":"Journal of Clinical Endocrinology and Metabolism","first-page":"2892","article-title":"Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy","volume":"91","author":"Durante","year":"2006","unstructured":"Durante CHaddy NBaudin ELeboulleux SHartl DTravagli JPCaillou BRicard MLumbroso JDDe Vathaire F, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. Journal of Clinical Endocrinology and Metabolism2006912892\u20132899. (https:\/\/doi.org\/10.1210\/jc.2005-2838)"},{"key":"bib5","series-title":"Thyroid","first-page":"674","article-title":"Redifferentiation of differentiated thyroid cancer: clinical insights from a narrative review of literature","volume":"33","author":"Van Nostrand","year":"2023","unstructured":"Van Nostrand DVeytsman IKulkarni KHeimlich L & Burman KD. Redifferentiation of differentiated thyroid cancer: clinical insights from a narrative review of literature. Thyroid202333674\u2013681. (https:\/\/doi.org\/10.1089\/thy.2022.0632)"},{"key":"bib6","series-title":"Cancers","first-page":"1382","article-title":"Radioiodine-refractory thyroid cancer: molecular basis of redifferentiation therapies, management, and novel therapies","volume":"11","author":"Aashiq","year":"2019","unstructured":"Aashiq MSilverman DANa\u2019ara STakahashi H & Amit M. Radioiodine-refractory thyroid cancer: molecular basis of redifferentiation therapies, management, and novel therapies. Cancers2019111382. (https:\/\/doi.org\/10.3390\/cancers11091382)"},{"key":"bib7","series-title":"Endocrine-Related Cancer","first-page":"T179","article-title":"Redifferentiation-facilitated radioiodine therapy in thyroid cancer","volume":"28","author":"Lamartina","year":"2021","unstructured":"Lamartina LAnizan NDupuy CLeboulleux S & Schlumberger M. Redifferentiation-facilitated radioiodine therapy in thyroid cancer. Endocrine-Related Cancer202128T179\u2013T191. (https:\/\/doi.org\/10.1530\/ERC-21-0024)"},{"key":"bib8","series-title":"Journal of Molecular Endocrinology","first-page":"R141","article-title":"Pathological processes and therapeutic advances in radioiodide refractory thyroid cancer","volume":"59","author":"Tesselaar","year":"2017","unstructured":"Tesselaar MHSmit JWNagarajah JNetea-Maier RT & Plantinga TS. Pathological processes and therapeutic advances in radioiodide refractory thyroid cancer. Journal of Molecular Endocrinology201759R141\u2013R154. (https:\/\/doi.org\/10.1530\/JME-17-0134)"},{"key":"bib9","series-title":"Clinical Cancer Research","first-page":"2401","article-title":"A Phase II redifferentiation trial with Dabrafenib-Trametinib and 131I in metastatic radioactive iodine refractory BRAF p. V600E-mutated differentiated thyroid cancer","volume":"29","author":"Leboulleux","year":"2023","unstructured":"Leboulleux SDo Cao CZerdoud SAttard MBournaud CLacroix LBenisvy DTa\u00efeb DBardet STerroir-Cassou-Mounat M, et al. A Phase II redifferentiation trial with Dabrafenib-Trametinib and 131I in metastatic radioactive iodine refractory BRAF p. V600E-mutated differentiated thyroid cancer. Clinical Cancer Research2023292401\u20132409. (https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-0046)"},{"key":"bib10","series-title":"New England Journal of Medicine","first-page":"623","article-title":"Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer","volume":"368","author":"Ho","year":"2013","unstructured":"Ho ALGrewal RKLeboeuf RSherman EJPfister DGDeandreis DPentlow KSZanzonico PBHaque SGavane S, et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. New England Journal of Medicine2013368623\u2013632. (https:\/\/doi.org\/10.1056\/NEJMoa1209288)"},{"key":"bib11","series-title":"Clinical Cancer Research","first-page":"1028","article-title":"Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib","volume":"21","author":"Rothenberg","year":"2015","unstructured":"Rothenberg SMMcFadden DGPalmer ELDaniels GH & Wirth LJ. Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib. Clinical Cancer Research2015211028\u20131035. (https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2915)"},{"key":"bib12","series-title":"Journal of the Endocrine Society","first-page":"285","article-title":"Restoring radioiodine uptake in BRAF V600E\u2013mutated papillary thyroid cancer","volume":"1","author":"Huillard","year":"2017","unstructured":"Huillard OTenenbaum FClerc JGoldwasser F & Groussin L. Restoring radioiodine uptake in BRAF V600E\u2013mutated papillary thyroid cancer. Journal of the Endocrine Society20171285\u2013287. (https:\/\/doi.org\/10.1210\/js.2016-1114)"},{"key":"bib13","series-title":"Journal of Clinical Endocrinology and Metabolism","first-page":"3698","article-title":"Targeted therapy in advanced thyroid cancer to resensitize tumors to radioactive iodine","volume":"103","author":"Jaber","year":"2018","unstructured":"Jaber TWaguespack SGCabanillas MEElbanan MVu TDadu RSherman SIAmit MSantos EBZafereo M, et al. Targeted therapy in advanced thyroid cancer to resensitize tumors to radioactive iodine. Journal of Clinical Endocrinology and Metabolism20181033698\u20133705. (https:\/\/doi.org\/10.1210\/jc.2018-00612)"},{"key":"bib14","series-title":"Journal of Clinical Endocrinology and Metabolism","first-page":"1417","article-title":"Vemurafenib redifferentiation of BRAF mutant, RAI-refractory thyroid cancers","volume":"104","author":"Dunn","year":"2019","unstructured":"Dunn LASherman EJBaxi SSTchekmedyian VGrewal RKLarson SMPentlow KSHaque STuttle RMSabra MM, et al. Vemurafenib redifferentiation of BRAF mutant, RAI-refractory thyroid cancers. Journal of Clinical Endocrinology and Metabolism20191041417\u20131428. (https:\/\/doi.org\/10.1210\/jc.2018-01478)"},{"key":"bib15","series-title":"Thyroid","first-page":"1634","article-title":"Mitogen-activated protein kinase pathway inhibition for redifferentiation of radioiodine refractory differentiated thyroid cancer: an evolving protocol","volume":"29","author":"Iravani","year":"2019","unstructured":"Iravani ASolomon BPattison DAJackson PRavi Kumar AKong GHofman MSAkhurst T & Hicks RJ. Mitogen-activated protein kinase pathway inhibition for redifferentiation of radioiodine refractory differentiated thyroid cancer: an evolving protocol. Thyroid2019291634\u20131645. (https:\/\/doi.org\/10.1089\/thy.2019.0143)"},{"key":"bib16","series-title":"Journal of Clinical Investigation","article-title":"NTRK and RET fusion\u2013directed therapy in pediatric thyroid cancer yields a tumor response and radioiodine uptake","volume":"131","author":"Lee","year":"2021","unstructured":"Lee YALee HIm S-WSong YSOh D-YKang HJWon J-KJung KCKwon DChung E-J, et al. NTRK and RET fusion\u2013directed therapy in pediatric thyroid cancer yields a tumor response and radioiodine uptake. Journal of Clinical Investigation2021131. (https:\/\/doi.org\/10.1172\/JCI144847)"},{"key":"bib17","series-title":"Thyroid","first-page":"1603","article-title":"Selpercatinib-enhanced radioiodine uptake in RET-rearranged thyroid cancer","volume":"31","author":"Groussin","year":"2021","unstructured":"Groussin LBessiene LArrondeau JGarinet SCochand-Priollet BLupo AZerbit JClerc J & Huillard O. Selpercatinib-enhanced radioiodine uptake in RET-rearranged thyroid cancer. Thyroid2021311603\u20131604. (https:\/\/doi.org\/10.1089\/thy.2021.0144)"},{"key":"bib18","series-title":"New England Journal of Medicine","first-page":"1686","article-title":"Larotrectinib-enhanced radioactive iodine uptake in advanced thyroid cancer","volume":"383","author":"Groussin","year":"2020","unstructured":"Groussin LClerc J & Huillard O. Larotrectinib-enhanced radioactive iodine uptake in advanced thyroid cancer. New England Journal of Medicine20203831686\u20131687. (https:\/\/doi.org\/10.1056\/NEJMc2023094)"},{"key":"bib19","series-title":"Thyroid","first-page":"273","article-title":"Enhancing radioiodine incorporation in BRAF-mutant, radioiodine-refractory thyroid cancers with vemurafenib and the anti-ErbB3 monoclonal antibody CDX-3379: results of a pilot clinical trial","volume":"32","author":"Tchekmedyian","year":"2022","unstructured":"Tchekmedyian VDunn LSherman EBaxi SSGrewal RKLarson SMPentlow KSHaque STuttle RMSabra MM, et al. Enhancing radioiodine incorporation in BRAF-mutant, radioiodine-refractory thyroid cancers with vemurafenib and the anti-ErbB3 monoclonal antibody CDX-3379: results of a pilot clinical trial. Thyroid202232273\u2013282. (https:\/\/doi.org\/10.1089\/thy.2021.0565)"},{"key":"bib20","series-title":"Thyroid","first-page":"594","article-title":"Redifferentiating effect of larotrectinib in NTRK-rearranged advanced radioactive-iodine refractory thyroid cancer","volume":"32","author":"Groussin","year":"2022","unstructured":"Groussin LTheodon HBessiene LBricaire LBonnet-Serrano FCochand-Priollet BLeroy KGarinet SPasmant EZerbit J, et al. Redifferentiating effect of larotrectinib in NTRK-rearranged advanced radioactive-iodine refractory thyroid cancer. Thyroid202232594\u2013598. (https:\/\/doi.org\/10.1089\/thy.2021.0524)"},{"key":"bib21","series-title":"Thyroid","first-page":"735","article-title":"Redifferentiation of a BRAFK601E-mutated poorly differentiated thyroid cancer patient with dabrafenib and trametinib treatment","volume":"29","author":"Leboulleux","year":"2019","unstructured":"Leboulleux SDupuy CLacroix LAttard MGrimaldi SCorre RRicard MNasr SBerdelou AHadoux J, et al. Redifferentiation of a BRAFK601E-mutated poorly differentiated thyroid cancer patient with dabrafenib and trametinib treatment. Thyroid201929735\u2013742. (https:\/\/doi.org\/10.1089\/thy.2018.0457)"},{"key":"bib22","series-title":"Cureus","first-page":"e17488","article-title":"Redifferentiation of BRAF V600E-mutated radioiodine refractory metastatic papillary thyroid cancer after treatment with dabrafenib and trametinib","volume":"13","author":"Jafri","year":"2021","unstructured":"Jafri S & Yaqub A. Redifferentiation of BRAF V600E-mutated radioiodine refractory metastatic papillary thyroid cancer after treatment with dabrafenib and trametinib. Cureus202113e17488. (https:\/\/doi.org\/10.7759\/cureus.17488)"},{"key":"bib23","series-title":"European Journal of Endocrinology","first-page":"923","article-title":"Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma","volume":"161","author":"Hoftijzer","year":"2009","unstructured":"Hoftijzer HHeemstra KAMorreau HStokkel MPCorssmit EPGelderblom HWeijers KPereira AMHuijberts MKapiteijn E, et al. Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. European Journal of Endocrinology2009161923\u2013931. (https:\/\/doi.org\/10.1530\/EJE-09-0702)"},{"key":"bib24","series-title":"Molecular Cancer Therapeutics","first-page":"169","article-title":"Digitalis-like compounds facilitate non-medullary thyroid cancer redifferentiation through intracellular Ca2+, FOS, and autophagy-dependent pathways","volume":"16","author":"Tesselaar","year":"2017","unstructured":"Tesselaar MHCrezee TSwarts HGGerrits DBoerman OCKoenderink JBStunnenberg HGNetea MGSmit JWANetea-Maier RT, et al. Digitalis-like compounds facilitate non-medullary thyroid cancer redifferentiation through intracellular Ca2+, FOS, and autophagy-dependent pathways. Molecular Cancer Therapeutics201716169\u2013181. (https:\/\/doi.org\/10.1158\/1535-7163.MCT-16-0460)"},{"key":"bib25","series-title":"Cellular Oncology","first-page":"611","article-title":"Digoxin treatment reactivates in vivo radioactive iodide uptake and correlates with favorable clinical outcome in non-medullary thyroid cancer","volume":"44","author":"Crezee","year":"2021","unstructured":"Crezee TTesselaar MHNagarajah JCorver WEMorreau JPritchard CKimura SKuiper JGvan Engen-van Grunsven ISmit JWA, et al. Digoxin treatment reactivates in vivo radioactive iodide uptake and correlates with favorable clinical outcome in non-medullary thyroid cancer. Cellular Oncology202144611\u2013625. (https:\/\/doi.org\/10.1007\/s13402-021-00588-y)"},{"key":"bib26","series-title":"Journal of Nuclear Medicine","first-page":"780","article-title":"Digitalislike compounds restore hNIS expression and iodide uptake capacity in anaplastic thyroid cancer","volume":"59","author":"Tesselaar","year":"2018","unstructured":"Tesselaar MHCrezee TSchuurmans IGerrits DNagarajah JBoerman OCvan Engen-van Grunsven ISmit JWANetea-Maier RT & Plantinga TS. Digitalislike compounds restore hNIS expression and iodide uptake capacity in anaplastic thyroid cancer. Journal of Nuclear Medicine201859780\u2013786. (https:\/\/doi.org\/10.2967\/jnumed.117.200675)"},{"key":"bib27","series-title":"Autophagy","first-page":"1195","article-title":"Autophagy activity is associated with membranous sodium iodide symporter expression and clinical response to radioiodine therapy in non-medullary thyroid cancer","volume":"12","author":"Plantinga","year":"2016","unstructured":"Plantinga TSTesselaar MHMorreau HCorssmit EPWillemsen BKKusters Bvan Engen-van Grunsven ACSmit JWA & Netea-Maier RT. Autophagy activity is associated with membranous sodium iodide symporter expression and clinical response to radioiodine therapy in non-medullary thyroid cancer. Autophagy2016121195\u20131205. (https:\/\/doi.org\/10.1080\/15548627.2016.1174802)"},{"key":"bib28","series-title":"BMC Cancer","first-page":"291","article-title":"Comprehensive routine diagnostic screening to identify predictive mutations, gene amplifications, and microsatellite instability in FFPE tumor material","volume":"20","author":"Steeghs","year":"2020","unstructured":"Steeghs EMKroeze LITops BBvan Kempen LCTer Elst AKastner-van Raaij AWHendriks-Cornelissen SJBHermsen MJWJansen EAMNederlof PM, et al. Comprehensive routine diagnostic screening to identify predictive mutations, gene amplifications, and microsatellite instability in FFPE tumor material. BMC Cancer202020291. (https:\/\/doi.org\/10.1186\/s12885-020-06785-6)"},{"key":"bib29","series-title":"Biochemistry","first-page":"8400","article-title":"Structure-function relationships in the sodium-potassium ATPase. alpha","volume":"27","author":"Price","year":"1988","unstructured":"Price EM & Lingrel JB. Structure-function relationships in the sodium-potassium ATPase. alpha. Biochemistry1988278400\u20138408. (https:\/\/doi.org\/10.1021\/bi00422a016)"},{"key":"bib30","series-title":"Cancer Research","first-page":"6688","article-title":"Inhibition of the sodium\/potassium ATPase impairs N-glycan expression and function","volume":"68","author":"Zavareh","year":"2008","unstructured":"Zavareh RBLau KSHurren RDatti AAshline DJGronda MCheung PSimpson CDLiu WWasylishen AR, et al. Inhibition of the sodium\/potassium ATPase impairs N-glycan expression and function. Cancer Research2008686688\u20136697. (https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-6833)"},{"key":"bib31","series-title":"Clinical Cancer Research","first-page":"4194","article-title":"Enhancing radioiodine incorporation into radioiodine-refractory thyroid cancer with MAPK inhibition (ERRITI): a single-center prospective two-arm study","volume":"28","author":"Weber","year":"2022","unstructured":"Weber MKersting DRiemann BBrandenburg TF\u00fchrer-Sakel DGr\u00fcnwald FKreissl MCDralle HWeber FSchmid KW, et al. Enhancing radioiodine incorporation into radioiodine-refractory thyroid cancer with MAPK inhibition (ERRITI): a single-center prospective two-arm study. Clinical Cancer Research2022284194\u20134202. (https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-0437)"},{"key":"bib32","series-title":"Molecular Endocrinology","first-page":"342","article-title":"PI3K is involved in the IGF-I inhibition of TSH-induced sodium\/iodide symporter gene expression","volume":"16","author":"Garc\u00eda","year":"2002","unstructured":"Garc\u00eda B & Santisteban P. PI3K is involved in the IGF-I inhibition of TSH-induced sodium\/iodide symporter gene expression. Molecular Endocrinology200216342\u2013352. (https:\/\/doi.org\/10.1210\/mend.16.2.0774)"},{"key":"bib33","series-title":"Journal of Clinical Endocrinology and Metabolism","first-page":"820","article-title":"Induction of thyroid gene expression and radioiodine uptake in thyroid cancer cells by targeting major signaling pathways","volume":"95","author":"Hou","year":"2010","unstructured":"Hou PBojdani E & Xing M. Induction of thyroid gene expression and radioiodine uptake in thyroid cancer cells by targeting major signaling pathways. Journal of Clinical Endocrinology and Metabolism201095820\u2013828. (https:\/\/doi.org\/10.1210\/jc.2009-1888)"},{"key":"bib34","series-title":"International Journal of Clinical and Experimental Medicine","first-page":"320","article-title":"Clinical significance of discordant findings between pre-therapy 123I and post-therapy 131I whole body scan in patients with thyroid cancer","volume":"6","author":"Bravo","year":"2013","unstructured":"Bravo PEGoudarzi BRana UTogni Filho PTCastillo RRababy CEwertz MZiessman HACooper DSLadenson PW, et al. Clinical significance of discordant findings between pre-therapy 123I and post-therapy 131I whole body scan in patients with thyroid cancer. International Journal of Clinical and Experimental Medicine20136320\u2013333."},{"key":"bib35","series-title":"European Journal of Nuclear Medicine and Molecular Imaging","first-page":"1012","article-title":"Iodine-123 as a diagnostic imaging agent in differentiated thyroid carcinoma: a comparison with iodine-131 post-treatment scanning and serum thyroglobulin measurement","volume":"34","author":"Urhan","year":"2007","unstructured":"Urhan MDadparvar SMavi AHouseni MChamroonrat WAlavi A & Mandel SJ. Iodine-123 as a diagnostic imaging agent in differentiated thyroid carcinoma: a comparison with iodine-131 post-treatment scanning and serum thyroglobulin measurement. European Journal of Nuclear Medicine and Molecular Imaging2007341012\u20131017. (https:\/\/doi.org\/10.1007\/s00259-006-0341-x)"},{"key":"bib36","series-title":"Radiology","first-page":"887","article-title":"Initial staging of differentiated thyroid carcinoma: continued utility of posttherapy 131I whole-body scintigraphy","volume":"246","author":"Donahue","year":"2008","unstructured":"Donahue KPShah NPLee SL & Oates ME. Initial staging of differentiated thyroid carcinoma: continued utility of posttherapy 131I whole-body scintigraphy. Radiology2008246887\u2013894. (https:\/\/doi.org\/10.1148\/radiol.2463061328)"},{"key":"bib37","series-title":"Journal of Clinical Endocrinology and Metabolism","first-page":"3144","article-title":"Radioactive iodine therapy does not improve cancer-specific survival in H\u00fcrthle cell carcinoma of the thyroid","volume":"107","author":"Wang","year":"2022","unstructured":"Wang XZheng XZhu JLi Z & Wei T. Radioactive iodine therapy does not improve cancer-specific survival in H\u00fcrthle cell carcinoma of the thyroid. Journal of Clinical Endocrinology and Metabolism20221073144\u20133151. (https:\/\/doi.org\/10.1210\/clinem\/dgac448)"},{"key":"bib38","series-title":"Journal of Clinical Endocrinology and Metabolism","first-page":"55","article-title":"Clinical and molecular features of H\u00fcrthle cell carcinoma of the thyroid","volume":"100","author":"Chindris","year":"2015","unstructured":"Chindris A-MCasler JDBernet VJRivera MThomas CKachergus JMNecela BMHay IDWestphal SAGrant CS, et al. Clinical and molecular features of H\u00fcrthle cell carcinoma of the thyroid. Journal of Clinical Endocrinology and Metabolism201510055\u201362. (https:\/\/doi.org\/10.1210\/jc.2014-1634)"}],"container-title":["European Thyroid Journal"],"original-title":[],"link":[{"URL":"https:\/\/etj.bioscientifica.com\/view\/journals\/etj\/13\/4\/ETJ-24-0153.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/etj.bioscientifica.com\/downloadpdf\/journals\/etj\/13\/4\/ETJ-24-0153.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/etj.bioscientifica.com\/downloadpdf\/journals\/etj\/13\/4\/ETJ-24-0153.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:52:05Z","timestamp":1784555525000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.bioscientifica.com\/etj\/article\/4313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,24]]},"references-count":38,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.1530\/etj-24-0153","relation":{},"ISSN":["2235-0802"],"issn-type":[{"value":"2235-0802","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,24]]}}}